nodes	percent_of_prediction	percent_of_DWPC	metapath
Desipramine—CYP2B6—Thiotepa—urinary bladder cancer	0.106	0.2	CbGbCtD
Desipramine—ABCB1—Mitomycin—urinary bladder cancer	0.0718	0.136	CbGbCtD
Desipramine—SLC22A2—Cisplatin—urinary bladder cancer	0.0564	0.107	CbGbCtD
Desipramine—CYP2A6—Fluorouracil—urinary bladder cancer	0.053	0.1	CbGbCtD
Desipramine—CYP3A4—Thiotepa—urinary bladder cancer	0.0326	0.0615	CbGbCtD
Desipramine—CYP2B6—Cisplatin—urinary bladder cancer	0.0293	0.0553	CbGbCtD
Desipramine—CYP2E1—Etoposide—urinary bladder cancer	0.0292	0.0551	CbGbCtD
Desipramine—ABCB1—Gemcitabine—urinary bladder cancer	0.0207	0.039	CbGbCtD
Desipramine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0202	0.0382	CbGbCtD
Desipramine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0196	0.0371	CbGbCtD
Desipramine—CYP1A2—Etoposide—urinary bladder cancer	0.0169	0.0319	CbGbCtD
Desipramine—ABCB1—Cisplatin—urinary bladder cancer	0.015	0.0283	CbGbCtD
Desipramine—ABCB1—Etoposide—urinary bladder cancer	0.0148	0.0279	CbGbCtD
Desipramine—CHRM3—ureter—urinary bladder cancer	0.0133	0.0935	CbGeAlD
Desipramine—SMPD1—urine—urinary bladder cancer	0.0116	0.0817	CbGeAlD
Desipramine—ABCB1—Doxorubicin—urinary bladder cancer	0.0101	0.019	CbGbCtD
Desipramine—ABCB1—Methotrexate—urinary bladder cancer	0.00975	0.0184	CbGbCtD
Desipramine—CHRM3—muscle of abdomen—urinary bladder cancer	0.00959	0.0673	CbGeAlD
Desipramine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00948	0.0179	CbGbCtD
Desipramine—CYP3A4—Etoposide—urinary bladder cancer	0.00884	0.0167	CbGbCtD
Desipramine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00603	0.0114	CbGbCtD
Desipramine—SMPD1—prostate gland—urinary bladder cancer	0.00418	0.0293	CbGeAlD
Desipramine—CYP2C19—urine—urinary bladder cancer	0.00402	0.0282	CbGeAlD
Desipramine—CYP1A2—urine—urinary bladder cancer	0.00329	0.0231	CbGeAlD
Desipramine—CYP2E1—urine—urinary bladder cancer	0.00296	0.0207	CbGeAlD
Desipramine—SMPD1—renal system—urinary bladder cancer	0.00285	0.02	CbGeAlD
Desipramine—HTR2A—urine—urinary bladder cancer	0.00257	0.018	CbGeAlD
Desipramine—CYP3A4—urine—urinary bladder cancer	0.00238	0.0167	CbGeAlD
Desipramine—CYP2D6—urine—urinary bladder cancer	0.00234	0.0164	CbGeAlD
Desipramine—SMPD1—female reproductive system—urinary bladder cancer	0.00228	0.016	CbGeAlD
Desipramine—CYP2A6—prostate gland—urinary bladder cancer	0.00225	0.0158	CbGeAlD
Desipramine—SMPD1—vagina—urinary bladder cancer	0.00206	0.0145	CbGeAlD
Desipramine—ORM1—prostate gland—urinary bladder cancer	0.00205	0.0144	CbGeAlD
Desipramine—CHRM5—epithelium—urinary bladder cancer	0.00204	0.0143	CbGeAlD
Desipramine—SLC22A4—prostate gland—urinary bladder cancer	0.00197	0.0138	CbGeAlD
Desipramine—CHRM2—prostate gland—urinary bladder cancer	0.00191	0.0134	CbGeAlD
Desipramine—CYP2A6—seminal vesicle—urinary bladder cancer	0.0019	0.0133	CbGeAlD
Desipramine—SLC22A2—renal system—urinary bladder cancer	0.00181	0.0127	CbGeAlD
Desipramine—ADRB1—prostate gland—urinary bladder cancer	0.0018	0.0127	CbGeAlD
Desipramine—SLC22A3—prostate gland—urinary bladder cancer	0.00179	0.0126	CbGeAlD
Desipramine—CHRM1—prostate gland—urinary bladder cancer	0.00174	0.0122	CbGeAlD
Desipramine—CYP2C18—vagina—urinary bladder cancer	0.00168	0.0118	CbGeAlD
Desipramine—SLC22A4—seminal vesicle—urinary bladder cancer	0.00166	0.0117	CbGeAlD
Desipramine—CHRM3—prostate gland—urinary bladder cancer	0.00155	0.0109	CbGeAlD
Desipramine—SLC22A3—seminal vesicle—urinary bladder cancer	0.00152	0.0106	CbGeAlD
Desipramine—SLC22A4—renal system—urinary bladder cancer	0.00134	0.00941	CbGeAlD
Desipramine—Carbamazepine—UGT2B7—urinary bladder cancer	0.00134	0.437	CrCbGaD
Desipramine—SMPD1—lymph node—urinary bladder cancer	0.00133	0.00936	CbGeAlD
Desipramine—SLC22A5—prostate gland—urinary bladder cancer	0.0013	0.00914	CbGeAlD
Desipramine—SLC22A1—renal system—urinary bladder cancer	0.00128	0.00896	CbGeAlD
Desipramine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.00127	0.0089	CbGeAlD
Desipramine—SLC22A3—renal system—urinary bladder cancer	0.00122	0.00857	CbGeAlD
Desipramine—SLC22A3—urethra—urinary bladder cancer	0.0012	0.00842	CbGeAlD
Desipramine—Benazepril—MTHFR—urinary bladder cancer	0.00113	0.371	CrCbGaD
Desipramine—ORM1—female reproductive system—urinary bladder cancer	0.00112	0.00784	CbGeAlD
Desipramine—CYP2A6—vagina—urinary bladder cancer	0.00111	0.00778	CbGeAlD
Desipramine—HRH1—prostate gland—urinary bladder cancer	0.0011	0.00775	CbGeAlD
Desipramine—SLC22A5—seminal vesicle—urinary bladder cancer	0.0011	0.00773	CbGeAlD
Desipramine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.0011	0.00772	CbGeAlD
Desipramine—SLC22A4—female reproductive system—urinary bladder cancer	0.00107	0.00754	CbGeAlD
Desipramine—CYP2E1—prostate gland—urinary bladder cancer	0.00106	0.00745	CbGeAlD
Desipramine—CHRM3—renal system—urinary bladder cancer	0.00106	0.00743	CbGeAlD
Desipramine—HTR1A—renal system—urinary bladder cancer	0.00106	0.0074	CbGeAlD
Desipramine—CHRM3—urethra—urinary bladder cancer	0.00104	0.0073	CbGeAlD
Desipramine—HTR2C—female reproductive system—urinary bladder cancer	0.001	0.00704	CbGeAlD
Desipramine—ADRB1—female reproductive system—urinary bladder cancer	0.000985	0.00691	CbGeAlD
Desipramine—SLC22A3—female reproductive system—urinary bladder cancer	0.000978	0.00686	CbGeAlD
Desipramine—SLC22A4—vagina—urinary bladder cancer	0.000972	0.00682	CbGeAlD
Desipramine—SLC6A4—female reproductive system—urinary bladder cancer	0.000952	0.00668	CbGeAlD
Desipramine—CHRM1—female reproductive system—urinary bladder cancer	0.000948	0.00665	CbGeAlD
Desipramine—SLC22A1—vagina—urinary bladder cancer	0.000925	0.00649	CbGeAlD
Desipramine—CYP2E1—seminal vesicle—urinary bladder cancer	0.000898	0.0063	CbGeAlD
Desipramine—SLC22A5—renal system—urinary bladder cancer	0.000888	0.00623	CbGeAlD
Desipramine—SLC22A3—vagina—urinary bladder cancer	0.000884	0.0062	CbGeAlD
Desipramine—SLC22A5—urethra—urinary bladder cancer	0.000872	0.00612	CbGeAlD
Desipramine—CHRM3—female reproductive system—urinary bladder cancer	0.000848	0.00595	CbGeAlD
Desipramine—SLC6A2—female reproductive system—urinary bladder cancer	0.000838	0.00588	CbGeAlD
Desipramine—HRH1—epithelium—urinary bladder cancer	0.000812	0.0057	CbGeAlD
Desipramine—CYP1A2—renal system—urinary bladder cancer	0.000804	0.00564	CbGeAlD
Desipramine—HRH1—smooth muscle tissue—urinary bladder cancer	0.000782	0.00549	CbGeAlD
Desipramine—CYP2B6—renal system—urinary bladder cancer	0.000771	0.00541	CbGeAlD
Desipramine—HRH1—urethra—urinary bladder cancer	0.00074	0.00519	CbGeAlD
Desipramine—CYP2E1—renal system—urinary bladder cancer	0.000724	0.00508	CbGeAlD
Desipramine—CYP2C19—vagina—urinary bladder cancer	0.000713	0.005	CbGeAlD
Desipramine—SLC22A5—female reproductive system—urinary bladder cancer	0.000711	0.00499	CbGeAlD
Desipramine—CYP2E1—urethra—urinary bladder cancer	0.000711	0.00499	CbGeAlD
Desipramine—HTR2A—epithelium—urinary bladder cancer	0.000678	0.00476	CbGeAlD
Desipramine—ORM1—lymph node—urinary bladder cancer	0.000653	0.00458	CbGeAlD
Desipramine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.000653	0.00458	CbGeAlD
Desipramine—SLC22A5—vagina—urinary bladder cancer	0.000643	0.00451	CbGeAlD
Desipramine—HTR2A—renal system—urinary bladder cancer	0.000629	0.00441	CbGeAlD
Desipramine—SLC22A4—lymph node—urinary bladder cancer	0.000629	0.00441	CbGeAlD
Desipramine—CYP2B6—female reproductive system—urinary bladder cancer	0.000617	0.00433	CbGeAlD
Desipramine—ABCB1—prostate gland—urinary bladder cancer	0.000605	0.00424	CbGeAlD
Desipramine—HRH1—female reproductive system—urinary bladder cancer	0.000603	0.00423	CbGeAlD
Desipramine—Clomipramine—GSTP1—urinary bladder cancer	0.000587	0.192	CrCbGaD
Desipramine—CYP3A4—renal system—urinary bladder cancer	0.000582	0.00408	CbGeAlD
Desipramine—CYP2E1—female reproductive system—urinary bladder cancer	0.000579	0.00407	CbGeAlD
Desipramine—CYP2D6—renal system—urinary bladder cancer	0.000573	0.00402	CbGeAlD
Desipramine—SLC22A3—lymph node—urinary bladder cancer	0.000572	0.00401	CbGeAlD
Desipramine—CYP2B6—vagina—urinary bladder cancer	0.000558	0.00392	CbGeAlD
Desipramine—HRH1—vagina—urinary bladder cancer	0.000545	0.00383	CbGeAlD
Desipramine—ABCB1—seminal vesicle—urinary bladder cancer	0.000511	0.00359	CbGeAlD
Desipramine—HTR2A—female reproductive system—urinary bladder cancer	0.000504	0.00353	CbGeAlD
Desipramine—SLC6A2—lymph node—urinary bladder cancer	0.00049	0.00344	CbGeAlD
Desipramine—CYP3A4—female reproductive system—urinary bladder cancer	0.000466	0.00327	CbGeAlD
Desipramine—CYP2D6—female reproductive system—urinary bladder cancer	0.000459	0.00322	CbGeAlD
Desipramine—HTR2A—vagina—urinary bladder cancer	0.000455	0.0032	CbGeAlD
Desipramine—ABCB1—epithelium—urinary bladder cancer	0.000444	0.00312	CbGeAlD
Desipramine—SLC22A5—lymph node—urinary bladder cancer	0.000416	0.00292	CbGeAlD
Desipramine—ABCB1—renal system—urinary bladder cancer	0.000412	0.00289	CbGeAlD
Desipramine—ABCB1—urethra—urinary bladder cancer	0.000405	0.00284	CbGeAlD
Desipramine—Oedema—Gemcitabine—urinary bladder cancer	0.00038	0.0021	CcSEcCtD
Desipramine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000378	0.00209	CcSEcCtD
Desipramine—Confusional state—Fluorouracil—urinary bladder cancer	0.000377	0.00208	CcSEcCtD
Desipramine—Convulsion—Cisplatin—urinary bladder cancer	0.000376	0.00208	CcSEcCtD
Desipramine—Oedema—Fluorouracil—urinary bladder cancer	0.000374	0.00207	CcSEcCtD
Desipramine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000372	0.00206	CcSEcCtD
Desipramine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000372	0.00206	CcSEcCtD
Desipramine—Ataxia—Methotrexate—urinary bladder cancer	0.000372	0.00206	CcSEcCtD
Desipramine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000369	0.00204	CcSEcCtD
Desipramine—Anxiety—Cisplatin—urinary bladder cancer	0.000368	0.00204	CcSEcCtD
Desipramine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000366	0.00202	CcSEcCtD
Desipramine—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000365	0.00202	CcSEcCtD
Desipramine—Discomfort—Cisplatin—urinary bladder cancer	0.000365	0.00202	CcSEcCtD
Desipramine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000365	0.00202	CcSEcCtD
Desipramine—Anorexia—Gemcitabine—urinary bladder cancer	0.000362	0.002	CcSEcCtD
Desipramine—Urticaria—Thiotepa—urinary bladder cancer	0.000359	0.00199	CcSEcCtD
Desipramine—Malaise—Etoposide—urinary bladder cancer	0.000359	0.00198	CcSEcCtD
Desipramine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000357	0.00198	CcSEcCtD
Desipramine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000357	0.00198	CcSEcCtD
Desipramine—Anorexia—Fluorouracil—urinary bladder cancer	0.000356	0.00197	CcSEcCtD
Desipramine—Purpura—Doxorubicin—urinary bladder cancer	0.000355	0.00197	CcSEcCtD
Desipramine—Hypotension—Gemcitabine—urinary bladder cancer	0.000355	0.00197	CcSEcCtD
Desipramine—Oedema—Cisplatin—urinary bladder cancer	0.000354	0.00196	CcSEcCtD
Desipramine—HRH1—lymph node—urinary bladder cancer	0.000353	0.00247	CbGeAlD
Desipramine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00035	0.00193	CcSEcCtD
Desipramine—Hypotension—Fluorouracil—urinary bladder cancer	0.000349	0.00193	CcSEcCtD
Desipramine—Ataxia—Epirubicin—urinary bladder cancer	0.000348	0.00193	CcSEcCtD
Desipramine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000347	0.00192	CcSEcCtD
Desipramine—Tachycardia—Cisplatin—urinary bladder cancer	0.000346	0.00191	CcSEcCtD
Desipramine—Convulsion—Etoposide—urinary bladder cancer	0.000345	0.00191	CcSEcCtD
Desipramine—Insomnia—Gemcitabine—urinary bladder cancer	0.000344	0.0019	CcSEcCtD
Desipramine—Hypertension—Etoposide—urinary bladder cancer	0.000343	0.0019	CcSEcCtD
Desipramine—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000342	0.00189	CcSEcCtD
Desipramine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000341	0.00189	CcSEcCtD
Desipramine—Eosinophilia—Methotrexate—urinary bladder cancer	0.000339	0.00187	CcSEcCtD
Desipramine—Insomnia—Fluorouracil—urinary bladder cancer	0.000338	0.00187	CcSEcCtD
Desipramine—Somnolence—Gemcitabine—urinary bladder cancer	0.000338	0.00187	CcSEcCtD
Desipramine—Anorexia—Cisplatin—urinary bladder cancer	0.000338	0.00187	CcSEcCtD
Desipramine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000336	0.00186	CcSEcCtD
Desipramine—Discomfort—Etoposide—urinary bladder cancer	0.000335	0.00185	CcSEcCtD
Desipramine—Somnolence—Fluorouracil—urinary bladder cancer	0.000332	0.00184	CcSEcCtD
Desipramine—Hypotension—Cisplatin—urinary bladder cancer	0.000331	0.00183	CcSEcCtD
Desipramine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000331	0.00183	CcSEcCtD
Desipramine—ABCB1—female reproductive system—urinary bladder cancer	0.00033	0.00232	CbGeAlD
Desipramine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000329	0.00182	CcSEcCtD
Desipramine—Fatigue—Gemcitabine—urinary bladder cancer	0.000328	0.00181	CcSEcCtD
Desipramine—Confusional state—Etoposide—urinary bladder cancer	0.000327	0.00181	CcSEcCtD
Desipramine—Constipation—Gemcitabine—urinary bladder cancer	0.000325	0.0018	CcSEcCtD
Desipramine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000325	0.0018	CcSEcCtD
Desipramine—Asthenia—Thiotepa—urinary bladder cancer	0.000324	0.00179	CcSEcCtD
Desipramine—Ataxia—Doxorubicin—urinary bladder cancer	0.000322	0.00178	CcSEcCtD
Desipramine—Pruritus—Thiotepa—urinary bladder cancer	0.00032	0.00177	CcSEcCtD
Desipramine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000318	0.00176	CcSEcCtD
Desipramine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000318	0.00176	CcSEcCtD
Desipramine—Tachycardia—Etoposide—urinary bladder cancer	0.000317	0.00175	CcSEcCtD
Desipramine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000317	0.00175	CcSEcCtD
Desipramine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000316	0.00175	CcSEcCtD
Desipramine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000315	0.00174	CcSEcCtD
Desipramine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000313	0.00173	CcSEcCtD
Desipramine—Anorexia—Etoposide—urinary bladder cancer	0.000309	0.00171	CcSEcCtD
Desipramine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000309	0.00171	CcSEcCtD
Desipramine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000308	0.0017	CcSEcCtD
Desipramine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000308	0.0017	CcSEcCtD
Desipramine—Drowsiness—Methotrexate—urinary bladder cancer	0.000305	0.00169	CcSEcCtD
Desipramine—Depression—Methotrexate—urinary bladder cancer	0.000304	0.00168	CcSEcCtD
Desipramine—Hypotension—Etoposide—urinary bladder cancer	0.000303	0.00168	CcSEcCtD
Desipramine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000301	0.00166	CcSEcCtD
Desipramine—Dizziness—Thiotepa—urinary bladder cancer	0.000299	0.00165	CcSEcCtD
Desipramine—ABCB1—vagina—urinary bladder cancer	0.000298	0.00209	CbGeAlD
Desipramine—Stomatitis—Methotrexate—urinary bladder cancer	0.000297	0.00164	CcSEcCtD
Desipramine—Urticaria—Fluorouracil—urinary bladder cancer	0.000297	0.00164	CcSEcCtD
Desipramine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000296	0.00164	CcSEcCtD
Desipramine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000296	0.00163	CcSEcCtD
Desipramine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000293	0.00162	CcSEcCtD
Desipramine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000292	0.00162	CcSEcCtD
Desipramine—Paraesthesia—Etoposide—urinary bladder cancer	0.000292	0.00161	CcSEcCtD
Desipramine—Weight increased—Epirubicin—urinary bladder cancer	0.000291	0.00161	CcSEcCtD
Desipramine—Somnolence—Etoposide—urinary bladder cancer	0.000289	0.0016	CcSEcCtD
Desipramine—Vomiting—Thiotepa—urinary bladder cancer	0.000287	0.00159	CcSEcCtD
Desipramine—Drowsiness—Epirubicin—urinary bladder cancer	0.000285	0.00158	CcSEcCtD
Desipramine—Rash—Thiotepa—urinary bladder cancer	0.000285	0.00158	CcSEcCtD
Desipramine—Dermatitis—Thiotepa—urinary bladder cancer	0.000285	0.00157	CcSEcCtD
Desipramine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000285	0.00157	CcSEcCtD
Desipramine—Headache—Thiotepa—urinary bladder cancer	0.000283	0.00157	CcSEcCtD
Desipramine—Decreased appetite—Etoposide—urinary bladder cancer	0.000282	0.00156	CcSEcCtD
Desipramine—Body temperature increased—Cisplatin—urinary bladder cancer	0.00028	0.00155	CcSEcCtD
Desipramine—Fatigue—Etoposide—urinary bladder cancer	0.00028	0.00155	CcSEcCtD
Desipramine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00028	0.00155	CcSEcCtD
Desipramine—Stomatitis—Epirubicin—urinary bladder cancer	0.000278	0.00154	CcSEcCtD
Desipramine—Jaundice—Epirubicin—urinary bladder cancer	0.000278	0.00154	CcSEcCtD
Desipramine—Constipation—Etoposide—urinary bladder cancer	0.000278	0.00154	CcSEcCtD
Desipramine—Hepatitis—Methotrexate—urinary bladder cancer	0.000274	0.00151	CcSEcCtD
Desipramine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000274	0.00151	CcSEcCtD
Desipramine—Asthenia—Gemcitabine—urinary bladder cancer	0.000273	0.00151	CcSEcCtD
Desipramine—Weight increased—Doxorubicin—urinary bladder cancer	0.000269	0.00149	CcSEcCtD
Desipramine—Pruritus—Gemcitabine—urinary bladder cancer	0.000269	0.00149	CcSEcCtD
Desipramine—Nausea—Thiotepa—urinary bladder cancer	0.000268	0.00148	CcSEcCtD
Desipramine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000268	0.00148	CcSEcCtD
Desipramine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000266	0.00147	CcSEcCtD
Desipramine—Pruritus—Fluorouracil—urinary bladder cancer	0.000264	0.00146	CcSEcCtD
Desipramine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000264	0.00146	CcSEcCtD
Desipramine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00026	0.00144	CcSEcCtD
Desipramine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000259	0.00143	CcSEcCtD
Desipramine—Urticaria—Etoposide—urinary bladder cancer	0.000258	0.00143	CcSEcCtD
Desipramine—Jaundice—Doxorubicin—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Desipramine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Desipramine—Abdominal pain—Etoposide—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Desipramine—Body temperature increased—Etoposide—urinary bladder cancer	0.000257	0.00142	CcSEcCtD
Desipramine—Hepatitis—Epirubicin—urinary bladder cancer	0.000256	0.00142	CcSEcCtD
Desipramine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000256	0.00141	CcSEcCtD
Desipramine—Tinnitus—Methotrexate—urinary bladder cancer	0.000255	0.00141	CcSEcCtD
Desipramine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000255	0.00141	CcSEcCtD
Desipramine—Asthenia—Cisplatin—urinary bladder cancer	0.000254	0.00141	CcSEcCtD
Desipramine—Dizziness—Fluorouracil—urinary bladder cancer	0.000247	0.00137	CcSEcCtD
Desipramine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000246	0.00136	CcSEcCtD
Desipramine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000242	0.00134	CcSEcCtD
Desipramine—Alopecia—Methotrexate—urinary bladder cancer	0.000242	0.00134	CcSEcCtD
Desipramine—Vomiting—Gemcitabine—urinary bladder cancer	0.000242	0.00134	CcSEcCtD
Desipramine—Rash—Gemcitabine—urinary bladder cancer	0.00024	0.00133	CcSEcCtD
Desipramine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00024	0.00132	CcSEcCtD
Desipramine—Tinnitus—Epirubicin—urinary bladder cancer	0.000239	0.00132	CcSEcCtD
Desipramine—Headache—Gemcitabine—urinary bladder cancer	0.000238	0.00132	CcSEcCtD
Desipramine—Flushing—Epirubicin—urinary bladder cancer	0.000238	0.00131	CcSEcCtD
Desipramine—Vomiting—Fluorouracil—urinary bladder cancer	0.000238	0.00131	CcSEcCtD
Desipramine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000237	0.00131	CcSEcCtD
Desipramine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000236	0.0013	CcSEcCtD
Desipramine—Rash—Fluorouracil—urinary bladder cancer	0.000236	0.0013	CcSEcCtD
Desipramine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000235	0.0013	CcSEcCtD
Desipramine—Headache—Fluorouracil—urinary bladder cancer	0.000234	0.0013	CcSEcCtD
Desipramine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000233	0.00129	CcSEcCtD
Desipramine—Asthenia—Etoposide—urinary bladder cancer	0.000233	0.00129	CcSEcCtD
Desipramine—Pruritus—Etoposide—urinary bladder cancer	0.00023	0.00127	CcSEcCtD
Desipramine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000229	0.00127	CcSEcCtD
Desipramine—Alopecia—Epirubicin—urinary bladder cancer	0.000226	0.00125	CcSEcCtD
Desipramine—Nausea—Gemcitabine—urinary bladder cancer	0.000226	0.00125	CcSEcCtD
Desipramine—Vomiting—Cisplatin—urinary bladder cancer	0.000225	0.00125	CcSEcCtD
Desipramine—Vision blurred—Methotrexate—urinary bladder cancer	0.000225	0.00124	CcSEcCtD
Desipramine—Rash—Cisplatin—urinary bladder cancer	0.000223	0.00124	CcSEcCtD
Desipramine—Dermatitis—Cisplatin—urinary bladder cancer	0.000223	0.00123	CcSEcCtD
Desipramine—Diarrhoea—Etoposide—urinary bladder cancer	0.000222	0.00123	CcSEcCtD
Desipramine—Nausea—Fluorouracil—urinary bladder cancer	0.000222	0.00123	CcSEcCtD
Desipramine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000221	0.00122	CcSEcCtD
Desipramine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000221	0.00122	CcSEcCtD
Desipramine—Flushing—Doxorubicin—urinary bladder cancer	0.00022	0.00122	CcSEcCtD
Desipramine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000218	0.00121	CcSEcCtD
Desipramine—Malaise—Methotrexate—urinary bladder cancer	0.000215	0.00119	CcSEcCtD
Desipramine—Dizziness—Etoposide—urinary bladder cancer	0.000215	0.00119	CcSEcCtD
Desipramine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000212	0.00117	CcSEcCtD
Desipramine—Nausea—Cisplatin—urinary bladder cancer	0.00021	0.00116	CcSEcCtD
Desipramine—Vision blurred—Epirubicin—urinary bladder cancer	0.00021	0.00116	CcSEcCtD
Desipramine—Alopecia—Doxorubicin—urinary bladder cancer	0.000209	0.00116	CcSEcCtD
Desipramine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000207	0.00114	CcSEcCtD
Desipramine—Convulsion—Methotrexate—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Desipramine—Vomiting—Etoposide—urinary bladder cancer	0.000206	0.00114	CcSEcCtD
Desipramine—Agitation—Epirubicin—urinary bladder cancer	0.000205	0.00113	CcSEcCtD
Desipramine—Rash—Etoposide—urinary bladder cancer	0.000205	0.00113	CcSEcCtD
Desipramine—Dermatitis—Etoposide—urinary bladder cancer	0.000205	0.00113	CcSEcCtD
Desipramine—Headache—Etoposide—urinary bladder cancer	0.000203	0.00112	CcSEcCtD
Desipramine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000202	0.00112	CcSEcCtD
Desipramine—Malaise—Epirubicin—urinary bladder cancer	0.000201	0.00111	CcSEcCtD
Desipramine—Discomfort—Methotrexate—urinary bladder cancer	0.0002	0.00111	CcSEcCtD
Desipramine—Palpitations—Epirubicin—urinary bladder cancer	0.000197	0.00109	CcSEcCtD
Desipramine—Confusional state—Methotrexate—urinary bladder cancer	0.000196	0.00108	CcSEcCtD
Desipramine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000194	0.00108	CcSEcCtD
Desipramine—Convulsion—Epirubicin—urinary bladder cancer	0.000193	0.00107	CcSEcCtD
Desipramine—ABCB1—lymph node—urinary bladder cancer	0.000193	0.00135	CbGeAlD
Desipramine—Nausea—Etoposide—urinary bladder cancer	0.000193	0.00107	CcSEcCtD
Desipramine—Hypertension—Epirubicin—urinary bladder cancer	0.000193	0.00106	CcSEcCtD
Desipramine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000191	0.00106	CcSEcCtD
Desipramine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00019	0.00105	CcSEcCtD
Desipramine—Agitation—Doxorubicin—urinary bladder cancer	0.00019	0.00105	CcSEcCtD
Desipramine—Anxiety—Epirubicin—urinary bladder cancer	0.000189	0.00105	CcSEcCtD
Desipramine—Discomfort—Epirubicin—urinary bladder cancer	0.000188	0.00104	CcSEcCtD
Desipramine—Malaise—Doxorubicin—urinary bladder cancer	0.000186	0.00103	CcSEcCtD
Desipramine—Dry mouth—Epirubicin—urinary bladder cancer	0.000186	0.00103	CcSEcCtD
Desipramine—Anorexia—Methotrexate—urinary bladder cancer	0.000185	0.00103	CcSEcCtD
Desipramine—Confusional state—Epirubicin—urinary bladder cancer	0.000184	0.00101	CcSEcCtD
Desipramine—Palpitations—Doxorubicin—urinary bladder cancer	0.000182	0.00101	CcSEcCtD
Desipramine—Oedema—Epirubicin—urinary bladder cancer	0.000182	0.00101	CcSEcCtD
Desipramine—Hypotension—Methotrexate—urinary bladder cancer	0.000182	0.00101	CcSEcCtD
Desipramine—Convulsion—Doxorubicin—urinary bladder cancer	0.000179	0.000989	CcSEcCtD
Desipramine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000178	0.000986	CcSEcCtD
Desipramine—Hypertension—Doxorubicin—urinary bladder cancer	0.000178	0.000985	CcSEcCtD
Desipramine—Tachycardia—Epirubicin—urinary bladder cancer	0.000178	0.000982	CcSEcCtD
Desipramine—Insomnia—Methotrexate—urinary bladder cancer	0.000176	0.000973	CcSEcCtD
Desipramine—Anxiety—Doxorubicin—urinary bladder cancer	0.000175	0.000968	CcSEcCtD
Desipramine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000175	0.000966	CcSEcCtD
Desipramine—Discomfort—Doxorubicin—urinary bladder cancer	0.000174	0.00096	CcSEcCtD
Desipramine—Anorexia—Epirubicin—urinary bladder cancer	0.000173	0.000959	CcSEcCtD
Desipramine—Somnolence—Methotrexate—urinary bladder cancer	0.000173	0.000956	CcSEcCtD
Desipramine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000172	0.00095	CcSEcCtD
Desipramine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000171	0.000947	CcSEcCtD
Desipramine—Hypotension—Epirubicin—urinary bladder cancer	0.00017	0.000941	CcSEcCtD
Desipramine—Confusional state—Doxorubicin—urinary bladder cancer	0.00017	0.000939	CcSEcCtD
Desipramine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000169	0.000935	CcSEcCtD
Desipramine—Oedema—Doxorubicin—urinary bladder cancer	0.000168	0.000931	CcSEcCtD
Desipramine—Fatigue—Methotrexate—urinary bladder cancer	0.000168	0.000927	CcSEcCtD
Desipramine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000165	0.000912	CcSEcCtD
Desipramine—Insomnia—Epirubicin—urinary bladder cancer	0.000165	0.00091	CcSEcCtD
Desipramine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000164	0.000909	CcSEcCtD
Desipramine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000163	0.000904	CcSEcCtD
Desipramine—Somnolence—Epirubicin—urinary bladder cancer	0.000162	0.000895	CcSEcCtD
Desipramine—Anorexia—Doxorubicin—urinary bladder cancer	0.000161	0.000888	CcSEcCtD
Desipramine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00016	0.000886	CcSEcCtD
Desipramine—Dyspepsia—Epirubicin—urinary bladder cancer	0.00016	0.000886	CcSEcCtD
Desipramine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000158	0.000875	CcSEcCtD
Desipramine—Hypotension—Doxorubicin—urinary bladder cancer	0.000157	0.00087	CcSEcCtD
Desipramine—Fatigue—Epirubicin—urinary bladder cancer	0.000157	0.000868	CcSEcCtD
Desipramine—Constipation—Epirubicin—urinary bladder cancer	0.000156	0.000861	CcSEcCtD
Desipramine—Urticaria—Methotrexate—urinary bladder cancer	0.000154	0.000854	CcSEcCtD
Desipramine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000154	0.00085	CcSEcCtD
Desipramine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000154	0.00085	CcSEcCtD
Desipramine—Insomnia—Doxorubicin—urinary bladder cancer	0.000152	0.000842	CcSEcCtD
Desipramine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000151	0.000836	CcSEcCtD
Desipramine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00015	0.000829	CcSEcCtD
Desipramine—Somnolence—Doxorubicin—urinary bladder cancer	0.00015	0.000828	CcSEcCtD
Desipramine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000148	0.00082	CcSEcCtD
Desipramine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000146	0.00081	CcSEcCtD
Desipramine—Fatigue—Doxorubicin—urinary bladder cancer	0.000145	0.000803	CcSEcCtD
Desipramine—Urticaria—Epirubicin—urinary bladder cancer	0.000145	0.0008	CcSEcCtD
Desipramine—Constipation—Doxorubicin—urinary bladder cancer	0.000144	0.000796	CcSEcCtD
Desipramine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000144	0.000796	CcSEcCtD
Desipramine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000144	0.000796	CcSEcCtD
Desipramine—Asthenia—Methotrexate—urinary bladder cancer	0.00014	0.000772	CcSEcCtD
Desipramine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000139	0.000768	CcSEcCtD
Desipramine—Pruritus—Methotrexate—urinary bladder cancer	0.000138	0.000761	CcSEcCtD
Desipramine—Urticaria—Doxorubicin—urinary bladder cancer	0.000134	0.00074	CcSEcCtD
Desipramine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000133	0.000736	CcSEcCtD
Desipramine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000133	0.000736	CcSEcCtD
Desipramine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000133	0.000736	CcSEcCtD
Desipramine—Asthenia—Epirubicin—urinary bladder cancer	0.000131	0.000722	CcSEcCtD
Desipramine—Pruritus—Epirubicin—urinary bladder cancer	0.000129	0.000712	CcSEcCtD
Desipramine—Dizziness—Methotrexate—urinary bladder cancer	0.000129	0.000711	CcSEcCtD
Desipramine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000125	0.000689	CcSEcCtD
Desipramine—Vomiting—Methotrexate—urinary bladder cancer	0.000124	0.000684	CcSEcCtD
Desipramine—Rash—Methotrexate—urinary bladder cancer	0.000123	0.000678	CcSEcCtD
Desipramine—Dermatitis—Methotrexate—urinary bladder cancer	0.000123	0.000678	CcSEcCtD
Desipramine—Headache—Methotrexate—urinary bladder cancer	0.000122	0.000674	CcSEcCtD
Desipramine—Asthenia—Doxorubicin—urinary bladder cancer	0.000121	0.000668	CcSEcCtD
Desipramine—Dizziness—Epirubicin—urinary bladder cancer	0.00012	0.000666	CcSEcCtD
Desipramine—Pruritus—Doxorubicin—urinary bladder cancer	0.000119	0.000659	CcSEcCtD
Desipramine—Vomiting—Epirubicin—urinary bladder cancer	0.000116	0.00064	CcSEcCtD
Desipramine—Nausea—Methotrexate—urinary bladder cancer	0.000116	0.000639	CcSEcCtD
Desipramine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000115	0.000637	CcSEcCtD
Desipramine—Rash—Epirubicin—urinary bladder cancer	0.000115	0.000635	CcSEcCtD
Desipramine—Dermatitis—Epirubicin—urinary bladder cancer	0.000115	0.000634	CcSEcCtD
Desipramine—Headache—Epirubicin—urinary bladder cancer	0.000114	0.000631	CcSEcCtD
Desipramine—Dizziness—Doxorubicin—urinary bladder cancer	0.000111	0.000616	CcSEcCtD
Desipramine—Nausea—Epirubicin—urinary bladder cancer	0.000108	0.000598	CcSEcCtD
Desipramine—Vomiting—Doxorubicin—urinary bladder cancer	0.000107	0.000592	CcSEcCtD
Desipramine—Rash—Doxorubicin—urinary bladder cancer	0.000106	0.000587	CcSEcCtD
Desipramine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000106	0.000587	CcSEcCtD
Desipramine—Headache—Doxorubicin—urinary bladder cancer	0.000105	0.000583	CcSEcCtD
Desipramine—Nausea—Doxorubicin—urinary bladder cancer	0.0001	0.000553	CcSEcCtD
Desipramine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	8.23e-06	5.72e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	8.2e-06	5.7e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CREBBP—urinary bladder cancer	8.18e-06	5.69e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	8.17e-06	5.69e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	8.16e-06	5.68e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	8.14e-06	5.66e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.13e-06	5.66e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	8.13e-06	5.65e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	8.11e-06	5.64e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	8.1e-06	5.64e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	8.1e-06	5.63e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CREBBP—urinary bladder cancer	8.1e-06	5.63e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	8.08e-06	5.62e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—IGF1—urinary bladder cancer	8.07e-06	5.62e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	8.06e-06	5.61e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—SRC—urinary bladder cancer	8.06e-06	5.6e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—EGFR—urinary bladder cancer	8.03e-06	5.59e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—PTGS2—urinary bladder cancer	8.01e-06	5.57e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—IGF1—urinary bladder cancer	7.99e-06	5.56e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	7.99e-06	5.56e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	7.98e-06	5.55e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	7.96e-06	5.54e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—EGFR—urinary bladder cancer	7.96e-06	5.53e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	7.95e-06	5.53e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.94e-06	5.52e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—EP300—urinary bladder cancer	7.93e-06	5.52e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	7.92e-06	5.51e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	7.87e-06	5.48e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	7.83e-06	5.45e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	7.78e-06	5.41e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	7.75e-06	5.39e-05	CbGpPWpGaD
Desipramine—SLC22A2—Metabolism—EP300—urinary bladder cancer	7.73e-06	5.38e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—SRC—urinary bladder cancer	7.71e-06	5.37e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	7.7e-06	5.36e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.65e-06	5.32e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	7.64e-06	5.31e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	7.61e-06	5.3e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	7.59e-06	5.28e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	7.58e-06	5.27e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	7.58e-06	5.27e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.57e-06	5.27e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	7.57e-06	5.27e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	7.56e-06	5.26e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	7.54e-06	5.25e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	7.53e-06	5.24e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	7.52e-06	5.23e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.5e-06	5.22e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	7.49e-06	5.21e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	7.46e-06	5.19e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	7.44e-06	5.18e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	7.44e-06	5.18e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	7.42e-06	5.16e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	7.41e-06	5.15e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	7.4e-06	5.14e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	7.38e-06	5.14e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	7.32e-06	5.09e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.28e-06	5.06e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	7.24e-06	5.04e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.24e-06	5.04e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	7.22e-06	5.02e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	7.22e-06	5.02e-05	CbGpPWpGaD
Desipramine—SLC22A1—Metabolism—EP300—urinary bladder cancer	7.21e-06	5.01e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	7.21e-06	5.01e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.19e-06	5e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.19e-06	5e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	7.17e-06	4.99e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.14e-06	4.97e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	7.13e-06	4.96e-05	CbGpPWpGaD
Desipramine—CYP2A6—Metabolism—EP300—urinary bladder cancer	7.1e-06	4.94e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	7.06e-06	4.91e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	7.06e-06	4.91e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	7.03e-06	4.89e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	7.02e-06	4.88e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	7.01e-06	4.88e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.99e-06	4.86e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—PTEN—urinary bladder cancer	6.98e-06	4.86e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	6.97e-06	4.85e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	6.91e-06	4.81e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	6.91e-06	4.8e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	6.89e-06	4.79e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	6.89e-06	4.79e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	6.89e-06	4.79e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	6.87e-06	4.78e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	6.86e-06	4.77e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	6.85e-06	4.76e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.83e-06	4.75e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	6.82e-06	4.74e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	6.82e-06	4.74e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	6.8e-06	4.73e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	6.8e-06	4.73e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	6.78e-06	4.72e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	6.78e-06	4.72e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.76e-06	4.7e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	6.76e-06	4.7e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	6.75e-06	4.69e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	6.67e-06	4.64e-05	CbGpPWpGaD
Desipramine—CHRM3—Metabolism—EP300—urinary bladder cancer	6.66e-06	4.63e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	6.66e-06	4.63e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	6.65e-06	4.62e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	6.62e-06	4.6e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	6.61e-06	4.6e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	6.61e-06	4.6e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.55e-06	4.56e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	6.53e-06	4.55e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	6.51e-06	4.53e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.51e-06	4.53e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	6.5e-06	4.52e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	6.49e-06	4.52e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	6.49e-06	4.52e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.47e-06	4.5e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	6.47e-06	4.5e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	6.46e-06	4.5e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.46e-06	4.49e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	6.45e-06	4.49e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	6.43e-06	4.47e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	6.39e-06	4.44e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	6.39e-06	4.44e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	6.36e-06	4.42e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.36e-06	4.42e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.36e-06	4.42e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	6.32e-06	4.4e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	6.29e-06	4.37e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	6.26e-06	4.35e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	6.24e-06	4.34e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	6.22e-06	4.33e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	6.2e-06	4.32e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.2e-06	4.32e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	6.2e-06	4.31e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	6.14e-06	4.27e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	6.1e-06	4.24e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	6.09e-06	4.23e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.09e-06	4.23e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	6.07e-06	4.22e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	6.05e-06	4.21e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.04e-06	4.2e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	6.02e-06	4.19e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	6.01e-06	4.18e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	6e-06	4.17e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	5.99e-06	4.17e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	5.98e-06	4.16e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	5.93e-06	4.12e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	5.92e-06	4.12e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	5.92e-06	4.12e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	5.91e-06	4.11e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.9e-06	4.11e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	5.89e-06	4.1e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.89e-06	4.1e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	5.89e-06	4.1e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	5.88e-06	4.09e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	5.88e-06	4.09e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	5.87e-06	4.08e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.87e-06	4.08e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	5.86e-06	4.07e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	5.85e-06	4.07e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.85e-06	4.07e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	5.84e-06	4.06e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	5.82e-06	4.05e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.79e-06	4.03e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	5.79e-06	4.03e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	5.79e-06	4.03e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	5.78e-06	4.02e-05	CbGpPWpGaD
Desipramine—CYP2B6—Metabolism—EP300—urinary bladder cancer	5.73e-06	3.98e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	5.71e-06	3.97e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	5.68e-06	3.95e-05	CbGpPWpGaD
Desipramine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	5.67e-06	3.94e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	5.67e-06	3.94e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	5.66e-06	3.94e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	5.64e-06	3.92e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.62e-06	3.91e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.62e-06	3.91e-05	CbGpPWpGaD
Desipramine—CYP2E1—Metabolism—EP300—urinary bladder cancer	5.61e-06	3.9e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	5.6e-06	3.9e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	5.59e-06	3.89e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	5.57e-06	3.87e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.55e-06	3.86e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.55e-06	3.86e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.55e-06	3.86e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	5.54e-06	3.85e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	5.51e-06	3.84e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	5.51e-06	3.83e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	5.47e-06	3.81e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	5.46e-06	3.8e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	5.45e-06	3.79e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	5.43e-06	3.78e-05	CbGpPWpGaD
Desipramine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	5.43e-06	3.78e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	5.41e-06	3.77e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	5.36e-06	3.73e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	5.35e-06	3.72e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.32e-06	3.7e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	5.23e-06	3.64e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.22e-06	3.63e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	5.21e-06	3.62e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.2e-06	3.62e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.16e-06	3.59e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.08e-06	3.53e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	4.97e-06	3.46e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.95e-06	3.44e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.91e-06	3.41e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	4.89e-06	3.4e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	4.88e-06	3.4e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	4.87e-06	3.39e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	4.86e-06	3.38e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	4.86e-06	3.38e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	4.85e-06	3.37e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	4.8e-06	3.34e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.79e-06	3.33e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	4.79e-06	3.33e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	4.78e-06	3.32e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	4.76e-06	3.31e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	4.76e-06	3.31e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	4.75e-06	3.3e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	4.7e-06	3.27e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	4.65e-06	3.24e-05	CbGpPWpGaD
Desipramine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	4.65e-06	3.24e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	4.63e-06	3.22e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.6e-06	3.2e-05	CbGpPWpGaD
Desipramine—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	4.55e-06	3.16e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.54e-06	3.16e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.52e-06	3.15e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	4.51e-06	3.14e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.5e-06	3.13e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	4.48e-06	3.12e-05	CbGpPWpGaD
Desipramine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	4.45e-06	3.09e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	4.44e-06	3.09e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.43e-06	3.08e-05	CbGpPWpGaD
Desipramine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	4.43e-06	3.08e-05	CbGpPWpGaD
Desipramine—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.33e-06	3.01e-05	CbGpPWpGaD
Desipramine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.22e-06	2.94e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.17e-06	2.9e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	4.08e-06	2.84e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.06e-06	2.82e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	4.02e-06	2.8e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	4.01e-06	2.79e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	4e-06	2.78e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	3.98e-06	2.77e-05	CbGpPWpGaD
Desipramine—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.98e-06	2.77e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.98e-06	2.77e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	3.95e-06	2.74e-05	CbGpPWpGaD
Desipramine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	3.91e-06	2.72e-05	CbGpPWpGaD
Desipramine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	3.84e-06	2.67e-05	CbGpPWpGaD
Desipramine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	3.84e-06	2.67e-05	CbGpPWpGaD
Desipramine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	3.82e-06	2.66e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.82e-06	2.66e-05	CbGpPWpGaD
Desipramine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	3.81e-06	2.65e-05	CbGpPWpGaD
Desipramine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	3.77e-06	2.62e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.54e-06	2.46e-05	CbGpPWpGaD
Desipramine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.37e-06	2.35e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.13e-06	2.18e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.73e-06	1.9e-05	CbGpPWpGaD
Desipramine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.6e-06	1.81e-05	CbGpPWpGaD
